Ruth Sequeiros
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ruth Sequeiros has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Sylvie Lantuejoul
Department of BioPathology, Centre Léon Bérard, Cancer Research Center of Lyon, Reference National Center MESOPATH and MESOBANK, Lyon, France
34 shared publications - Christophe Blanquart
Nantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d’Angers, CRCI2NA, Nantes, France
33 shared publications - Clément Meiller
INSERM, Université Paris Cité, Sorbonne Université, Centre de Recherche des Cordeliers, Functional Genomics of Solid Tumors, Paris, France
33 shared publications - Didier Jean
INSERM, Universite Paris Cite, Sorbonne Universite, Centre de Recherche des Cordeliers, F-75006 Paris, France
33 shared publications - Françoise Le Pimpec-Barthes
Department of Thoracic Surgery and Lung Transplantation, Hôpital Européen Georges-Pompidou, Assistance Publique—Hôpitaux de Paris, Université Paris Cité , Paris, France
33 shared publications - Jean-Baptiste Assié
Unité de pneumologie, Assistance publique – Hôpitaux de Paris (AP-HP), hôpitaux universitaires Henri-Mondor, DHU A-TVB, université Paris-Est-Créteil, 94010 Créteil, France
33 shared publications
Latest Publications
- 20 November 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (47)
Subclonal evolution can shape the transition toward a sarcomatoid phenotype in pleural mesothelioma
A better understanding of intratumor heterogeneity in pleural mesothelioma (PM) is crucial to implementing precision medicine for this deadly cancer. Using single-cell RNA sequencing approaches on tumor samples and derived primary cell lines, we defined four phenotypic cell types, related to overall survival in larger bulk cohorts: epithelioid, sarcomatoid, intermediate, and nondifferentiated. Some tumor samples showed intratumor phenotypic heterogeneity, associated with subclonal evolution, in which sarcomatoid cells can emerge from parental cells with an intermediate phenotype following the acquisition of copy number variations. Subclones were conserved in cell lines and retained their specific phenotypes, suggesting high phenotypic heritability. Spatial transcriptomics illustrated the link between phenotypic and subclonal evolution, showing that subclonal cells were colocalized and exhibited specific morphologies within the tumor tissue. Our study provides a comprehensive single-cell profiling of PM tumor cells and reveals a link between phenotypic evolution, clonal architecture, and tumor spatial organization.
- 20 November 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (47)
Subclonal evolution can shape the transition toward a sarcomatoid phenotype in pleural mesothelioma
A better understanding of intratumor heterogeneity in pleural mesothelioma (PM) is crucial to implementing precision medicine for this deadly cancer. Using single-cell RNA sequencing approaches on tumor samples and derived primary cell lines, we defined four phenotypic cell types, related to overall survival in larger bulk cohorts: epithelioid, sarcomatoid, intermediate, and nondifferentiated. Some tumor samples showed intratumor phenotypic heterogeneity, associated with subclonal evolution, in which sarcomatoid cells can emerge from parental cells with an intermediate phenotype following the acquisition of copy number variations. Subclones were conserved in cell lines and retained their specific phenotypes, suggesting high phenotypic heritability. Spatial transcriptomics illustrated the link between phenotypic and subclonal evolution, showing that subclonal cells were colocalized and exhibited specific morphologies within the tumor tissue. Our study provides a comprehensive single-cell profiling of PM tumor cells and reveals a link between phenotypic evolution, clonal architecture, and tumor spatial organization.
- Open Access
Self-Supervised AI Discovery of Histomorphological Phenotypes from Routine Mesothelioma Biopsies
Accurate subtype diagnosis is essential for guiding therapy and predicting patient outcome in malignant mesothelioma. Most computational pathology models are trained on large tissue images from resection specimens, which maximises information for training but limits model relevance in real-world diagnostic settings where small biopsies are the most usual tissue source. In this work, we assembled a large multicentre cohort of HES- and HPS-stained mesothelioma biopsy slides. We used a self-supervised learning model to evaluate the associations of biopsy-driven morphology patterns with histological subtype, molecular markers, and survival. The discovered histomorphology patterns captured a continuum of tissue phenotypes spanning epithelioid, sarcomatoid, and non-tumour morphologies. Also, patient-level HPC representations achieved excellent performance for distinguishing epithelioid from non-epithelioid mesothelioma (AUC = 0.94) and demonstrated predictive value for immunohistochemistry (IHC) markers. Additionally, HPC-derived features alone achieved performance comparable to established clinical and molecular variables (C-index = 0.65), while integration of HPCs with clinical and marker information improved performance to a C-index of 0.69. Several HPCs were significantly associated with favourable or adverse prognosis and reflected known subtype-specific biological patterns. In conclusion, self-supervised learning can discover interpretable histomorphological phenotypes directly from routine mesothelioma biopsies without further training. These AI-derived phenotypes capture clinically and biologically relevant information, linking tissue architecture to molecular characteristics, histological subtypes, and patient outcomes. The proposed framework provides a thorough evaluation of real-world biopsy data using a pre-trained model, without the need for computationally intensive retraining, and addresses the question of whether SSL-based AI can be deployed out of the box in clinical settings.
Open AccessSelf-Supervised AI Discovery of Histomorphological Phenotypes from Routine Mesothelioma Biopsies
Accurate subtype diagnosis is essential for guiding therapy and predicting patient outcome in malignant mesothelioma. Most computational pathology models are trained on large tissue images from resection specimens, which maximises information for training but limits model relevance in real-world diagnostic settings where small biopsies are the most usual tissue source. In this work, we assembled a large multicentre cohort of HES- and HPS-stained mesothelioma biopsy slides. We used a self-supervised learning model to evaluate the associations of biopsy-driven morphology patterns with histological subtype, molecular markers, and survival. The discovered histomorphology patterns captured a continuum of tissue phenotypes spanning epithelioid, sarcomatoid, and non-tumour morphologies. Also, patient-level HPC representations achieved excellent performance for distinguishing epithelioid from non-epithelioid mesothelioma (AUC = 0.94) and demonstrated predictive value for immunohistochemistry (IHC) markers. Additionally, HPC-derived features alone achieved performance comparable to established clinical and molecular variables (C-index = 0.65), while integration of HPCs with clinical and marker information improved performance to a C-index of 0.69. Several HPCs were significantly associated with favourable or adverse prognosis and reflected known subtype-specific biological patterns. In conclusion, self-supervised learning can discover interpretable histomorphological phenotypes directly from routine mesothelioma biopsies without further training. These AI-derived phenotypes capture clinically and biologically relevant information, linking tissue architecture to molecular characteristics, histological subtypes, and patient outcomes. The proposed framework provides a thorough evaluation of real-world biopsy data using a pre-trained model, without the need for computationally intensive retraining, and addresses the question of whether SSL-based AI can be deployed out of the box in clinical settings.
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S20 from Pharmacogenomic Characterization of a Large Cohort of Patient-Derived Cell Lines Identifies Therapeutic Strategies for Pleural Mesothelioma
Dose-response screening of 20 drugs, including pemetrexed and cisplatin, alone or in combination.
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S20 from Pharmacogenomic Characterization of a Large Cohort of Patient-Derived Cell Lines Identifies Therapeutic Strategies for Pleural Mesothelioma
Dose-response screening of 20 drugs, including pemetrexed and cisplatin, alone or in combination.
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S15 from Pharmacogenomic Characterization of a Large Cohort of Patient-Derived Cell Lines Identifies Therapeutic Strategies for Pleural Mesothelioma
Consensus matrix of the clustering based on methylome data.
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S15 from Pharmacogenomic Characterization of a Large Cohort of Patient-Derived Cell Lines Identifies Therapeutic Strategies for Pleural Mesothelioma
Consensus matrix of the clustering based on methylome data.
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S11 from Pharmacogenomic Characterization of a Large Cohort of Patient-Derived Cell Lines Identifies Therapeutic Strategies for Pleural Mesothelioma
Contribution of epithelial-to-mesenchymal transition (EMT) to cell line heterogeneity.
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S11 from Pharmacogenomic Characterization of a Large Cohort of Patient-Derived Cell Lines Identifies Therapeutic Strategies for Pleural Mesothelioma
Contribution of epithelial-to-mesenchymal transition (EMT) to cell line heterogeneity.
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Pharmacogenomic Characterization of a Large Cohort of Patient-Derived Cell Lines Identifies Therapeutic Strategies for Pleural Mesothelioma
Distribution of the genetic alterations in the Hippo core pathway plus NF2, SWI/SNF chromatin remodelling complex pathway and homologous recombination repair pathway.
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Pharmacogenomic Characterization of a Large Cohort of Patient-Derived Cell Lines Identifies Therapeutic Strategies for Pleural Mesothelioma
Distribution of the genetic alterations in the Hippo core pathway plus NF2, SWI/SNF chromatin remodelling complex pathway and homologous recombination repair pathway.
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from Pharmacogenomic Characterization of a Large Cohort of Patient-Derived Cell Lines Identifies Therapeutic Strategies for Pleural Mesothelioma
Histologic and molecular characteristics of transcriptome subtypes.
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from Pharmacogenomic Characterization of a Large Cohort of Patient-Derived Cell Lines Identifies Therapeutic Strategies for Pleural Mesothelioma
Histologic and molecular characteristics of transcriptome subtypes.
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S21 from Pharmacogenomic Characterization of a Large Cohort of Patient-Derived Cell Lines Identifies Therapeutic Strategies for Pleural Mesothelioma
Classification of the drugs based on their sensitivity profiles across cell lines.
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S21 from Pharmacogenomic Characterization of a Large Cohort of Patient-Derived Cell Lines Identifies Therapeutic Strategies for Pleural Mesothelioma
Classification of the drugs based on their sensitivity profiles across cell lines.
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Pharmacogenomic Characterization of a Large Cohort of Patient-Derived Cell Lines Identifies Therapeutic Strategies for Pleural Mesothelioma
Effect of genetic alterations on TERT gene expression.
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Pharmacogenomic Characterization of a Large Cohort of Patient-Derived Cell Lines Identifies Therapeutic Strategies for Pleural Mesothelioma
Effect of genetic alterations on TERT gene expression.